Photocure ASA
Photocure ASA, together with its subsidiaries, engages in the research, development, production, distribution, marketing, and sale of pharmaceutical products. It operates through Commercial Franchise and Development Portfolio segments. The company offers Hexvix/Cysview for the detection and management of bladder cancer. It also develops Cevira for the treatment of human papilloma virus-induced ce… Read more
Photocure ASA (PHCUF) - Total Assets
Latest total assets as of September 2025: $693.75 Million USD
Based on the latest financial reports, Photocure ASA (PHCUF) holds total assets worth $693.75 Million USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Photocure ASA - Total Assets Trend (2002–2024)
This chart illustrates how Photocure ASA’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Photocure ASA - Asset Composition Analysis
Current Asset Composition (December 2024)
Photocure ASA's total assets of $693.75 Million consist of 57.4% current assets and 42.6% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 39.1% |
| Accounts Receivable | $72.23 Million | 9.8% |
| Inventory | $39.54 Million | 5.4% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $111.23 Million | 15.1% |
| Goodwill | $144.00 Million | 19.5% |
Asset Composition Trend (2002–2024)
This chart illustrates how Photocure ASA's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Photocure ASA's current assets represent 57.4% of total assets in 2024, a decrease from 95.9% in 2002.
- Cash Position: Cash and equivalents constituted 39.1% of total assets in 2024, up from 11.4% in 2002.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 34.0% of total assets, an increase from 0.0% in 2002.
- Asset Diversification: The largest asset category is goodwill at 19.5% of total assets.
Photocure ASA Competitors by Total Assets
Key competitors of Photocure ASA based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF
|
USA | $67.26 Billion |
|
Kamada
NASDAQ:KMDA
|
USA | $378.79 Million |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
Photocure ASA - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Strong asset utilization - Photocure ASA generates 0.71x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Photocure ASA is currently not profitable relative to its asset base.
Photocure ASA - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.25 | 5.16 | 5.17 |
| Quick Ratio | 3.87 | 4.73 | 4.80 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $285.29 Million | $ 321.12 Million | $ 332.46 Million |
Photocure ASA - Advanced Valuation Insights
This section examines the relationship between Photocure ASA's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.63 |
| Latest Market Cap to Assets Ratio | 0.12 |
| Asset Growth Rate (YoY) | 3.8% |
| Total Assets | $739.09 Million |
| Market Capitalization | $86.14 Million USD |
Valuation Analysis
Below Book Valuation: The market values Photocure ASA's assets below their book value (0.12 x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Photocure ASA's assets grew by 3.8% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Photocure ASA (2002–2024)
The table below shows the annual total assets of Photocure ASA from 2002 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $739.09 Million | +3.81% |
| 2023-12-31 | $711.97 Million | -0.98% |
| 2022-12-31 | $719.03 Million | -8.94% |
| 2021-12-31 | $789.65 Million | +1.75% |
| 2020-12-31 | $776.05 Million | +201.55% |
| 2019-12-31 | $257.35 Million | +11.31% |
| 2018-12-31 | $231.20 Million | -12.13% |
| 2017-12-31 | $263.10 Million | -7.96% |
| 2016-12-31 | $285.85 Million | +15.24% |
| 2015-12-31 | $248.06 Million | -8.32% |
| 2014-12-31 | $270.58 Million | -10.32% |
| 2013-12-31 | $301.73 Million | -30.31% |
| 2012-12-31 | $432.98 Million | -14.97% |
| 2011-12-31 | $509.18 Million | -0.91% |
| 2010-12-31 | $513.84 Million | +12.47% |
| 2009-12-31 | $456.86 Million | +92.08% |
| 2008-12-31 | $237.85 Million | -21.08% |
| 2007-12-31 | $301.39 Million | -19.72% |
| 2006-12-31 | $375.42 Million | +255.16% |
| 2005-12-31 | $105.70 Million | -39.15% |
| 2004-12-31 | $173.71 Million | -25.57% |
| 2003-12-31 | $233.40 Million | -21.94% |
| 2002-12-31 | $299.01 Million | -- |